Executive Summary
=================

1. Objective
------------

Rheumatoid Arthritis (RA) is a chronic disease with underlying pathologic mechanisms which are not fully understood and where no cure exists to date. The main symptoms of RA are painful inflammations in joints leading to irreversible destructions associated with a loss in functionality.

Conventional drug therapies use unspecific immunsupressive agents such as methotrexate, azathioprim or gold preparations which lead to unsatisfactory long term results. Biologicals such as etanercept and infliximab promise to interfere more substantially with pathologic mechanisms in antagonising TNF-α, a cytokine which plays a central role in the RA causing inflammation process.

The HTA report examines the effectiveness of etanercept and infliximab in decreasing inflammation activity in order to sustain functionality and prevent irreversible destructions of joints. The focus of the report is on two indications: severe forms of RA, where conventional therapies failed, and early stages of RA without prior testing of conventional therapies for response.

From the social as well as from the individual perspective RA is a substantial financial burden. Especially the high rates of indirect and intangible costs of RA are of major concern when assessing the health economic consequences of RA. A major proportion of the direct costs is caused by secondary care whereas the costs for medication account only for 15% of the total costs. To date biologicals play an inferior role in treating RA in Germany. From the health economic perspective the cost-effectiveness of biologicals is examined and the circumstances are to be assessed under which biologicals can be considered cost-effective. Hence, further health economic research needs are assessed.

2. Methods
----------

The portion of the population of concern in the report are adult patients. In order to assess available evidence a systematic search in scientific databases and in relevant journals has been conducted. This assessment was complemented by a handsearch in relevant journals and on the manufactures\` internet pages. The available information was assessed by using established evidence-medicine based criteria and the checklists prepared by the German Scientific Working Group for Technology Assessment in Health Care.

The health economic consequences of the treatment of RA with TNF-α-antagonists were assessed in a systematic search in health economic databases (DARE, EMBASE, NEED, and MEDLINE) and an extensive handsearch in health economic journals. International HTA-institutions were contacted in order to identify relevant information. Publications had be written in German, English and French.

3. Results
----------

Neither HTA reports nor meta-studies could be identified. Twelve clinical studies were found and analysed. National and international guidelines, expert options, non-systematic reviews, case reports and publications concerning the safety of TNF-α-antagonists where included in the assessment of the clinical effectiveness. 137 publications were identified.

The primary clinical goal of assessing TNF-α-antagonists in the treatment of RA was the suppression of the clinical activity and a delay of the destruction of RA-affected joints. Clinical response was assessed using standardized response criteria on the basis of semi-quantative instruments using 20%, 50% or 70% improvement levels.

In patients with refractive RA TNF-α-antagonists are significantly more effective than methotrexate in the reduction of symptoms, in stabilising functionality and quality of life as well as structural destruction of the joints. The faster onset of clinical response using TNF-α-antagonists compared with methotrexate can be observed. Nevertheless the clinical response and the inhibition of progression radiologic lesions equal within several months. Severe complications of TNF-α-antagonists are rare and their rate does not differ significantly between groups. Case studies describe the risk of severe infections, especially tuberculosis. Therapeutic guidelines and expert options suggest TNF-α-antagonists in the treatment of patients with refractive RA after insufficient response to standard therapy. No head-to-head-studies between infliximab and etanercept exist to date.

Apart from analytic decision models health economic studies assess the cost-effectiveness of which TNF-α-antagonists are lacking. Based on decision models it can be concluded that a combination therapy of hydroxychloroquin (HCQ), sulfasalazin (SASP) and methotrexate as well as a combination of etanercept and methotrexate can be considered cost-effective in principal.

4. Conclusion
-------------

TNF-α-antagonists are effective in patients with insufficient response to a standard therapy with methotrexte. In those patients TNF-α-antagonists are significantly more effective compared to the standard therapy. This applies to lowering the inflammation activity as well as to pain relief, improvement of functionality and slowing down joint destruction.
